BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26937902)

  • 21. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
    Laugesen CS; Ostri C; Brynskov T; Lund-Andersen H; Larsen M; Vorum H; Sørensen TL
    Acta Ophthalmol; 2017 Feb; 95(1):28-32. PubMed ID: 27473397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.
    Abd Elhamid AH; Mohamed AAEA; Khattab AM
    BMC Ophthalmol; 2020 Apr; 20(1):130. PubMed ID: 32252674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
    Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal Ranibizumab for myopic choroidal neovascularization after pars plana vitrectomy and silicone oil tamponade.
    Cascavilla ML; Querques G; Querques L; Codenotti M; Bandello F
    Eur J Ophthalmol; 2013; 23(6):913-6. PubMed ID: 23813105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
    JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.
    Filho JA; Messias A; Almeida FP; Ribeiro JA; Costa RA; Scott IU; Jorge R
    Acta Ophthalmol; 2011 Nov; 89(7):e567-72. PubMed ID: 21726427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study.
    Yao TT; Yang Y; Jin XL; Wang YX; Zhou YL; Xu AJ; He FL; Wang ZY
    Acta Ophthalmol; 2020 Nov; 98(7):e795-e800. PubMed ID: 32114709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes of sutureless 25-G+ pars-plana vitrectomy for the management of diabetic tractional retinal detachment.
    Mikhail M; Ali-Ridha A; Chorfi S; Kapusta MA
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):255-261. PubMed ID: 27480177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Proportional Reflux During Pars Plana Vitrectomy for Tractional Retinal Detachments.
    Jain S; Agarwal A; Aggarwal K; Gupta V
    Ophthalmic Surg Lasers Imaging Retina; 2019 Feb; 50(2):113-115. PubMed ID: 30768219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results of vitrectomy without endotamponade in proliferative diabetic retinopathy with tractional retinal detachment.
    Tao Y; Jiang YR; Li XX; Gao L; Jonas JB
    Retina; 2010 Mar; 30(3):447-51. PubMed ID: 20216292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
    Naser H; Koss MJ; Singh P; Koch F
    Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.
    Gupta A; Bansal R; Gupta V; Dogra MR
    Int Ophthalmol; 2012 Apr; 32(2):135-44. PubMed ID: 22450558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
    di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Smith JM; Steel DH
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.
    Ebneter A; Wolf S; Zinkernagel MS
    Br J Ophthalmol; 2016 Mar; 100(3):365-70. PubMed ID: 26187951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment.
    Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F
    Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426
    [No Abstract]   [Full Text] [Related]  

  • 37. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
    Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy.
    Hu L; Chen Q; Du Z; Wang W; Zhao G
    Int Ophthalmol; 2021 May; 41(5):1635-1642. PubMed ID: 33538931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
    Diabetic Retinopathy Clinical Research Network*
    JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    ; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
    JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.